Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

News Release

Printer Friendly Version View printer-friendly version
<< Back
Portola Pharmaceuticals Announces Betrixaban and AndexXa™ (andexanet alfa) Presentations at ACC.17

SOUTH SAN FRANCISCO, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that new data from the pivotal Phase 3 APEX Study of the Company’s investigational drug betrixaban will be presented in a poster session at the upcoming American College of Cardiology’s (ACC) 66th Annual Scientific Session & Expo, which is taking place from March 17-19 at the Walter E. Washington Convention Center in Washington, D.C. Additionally, clinical data on betrixaban and on the Company’s investigational agent AndexXa™ (andexanet alfa) will be discussed during an oral session titled, “Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention.”

Betrixaban, which has Fast Track designation from the U.S. Food and Drug Administration (FDA), is an oral, once-daily Factor Xa inhibitor anticoagulant in development for the extended prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE. AndexXa, a U.S. Food and Drug Administration (FDA)-designated Breakthrough Therapy, is in development for patients treated with a direct (apixaban, rivaroxaban or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The betrixaban poster will include additional data that is not available in the abstract, which is currently available on the ACC website.


  • Abstract Title: Extended Duration Betrixaban Reduces the Risk of Venous Thromboembolism Versus Standard Duration Enoxaparin in the Post Parenteral Period Among Hospitalized Medically Ill Patients
    Poster #: 055
    Presenting Author: Serge Korjian, M.D., Beth Israel Deaconess Medical Center, Boston 
    Session Title: Diabetes and Other Issues in Cardiovascular Prevention 
    Presentation Date and Time: Sunday, March 19, 9:45-10:30 a.m. ET
    Presentation Location: Poster Hall, Hall C

  • Presentation Title: Extended Pharmacological Thromboprophylaxis at Hospital Discharge for High Risk Medical Patients
    Presenting Author: Alexander (Ander) T. Cohen, MBBS, M.Sc., M.D., FRACP, APEX Co-Principal Investigator and Co-Chairman of the APEX Executive Committee and consultant physician at Guy’s and St Thomas’ NHS Foundation Trust
    Session Title: Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention
    Session Number: 637
    Presentation Date and Time: Friday, March 17, 2:48-3:00 p.m. ET
    Presentation Location: Room 209 C

AndexXa™ (andexanet alfa)

  • Presentation Title: Managing Life-threatening Bleeding in Patients Taking Non-Vitamin K Oral Anticoagulants: When and How to Use Reversal Agents
    Presenting Author: Samuel Goldhaber, M.D., senior physician, Brigham and Women’s Hospital, Boston  
    Session Title: Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention
    Session Number: 637
    Presentation Date and Time: Friday, March 17, 2:24-2:36 p.m. ET
    Presentation Location: Room 209 C

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit and follow the Company on Twitter @Portola_Pharma.

Investor Contact:
Ana Kapor
Portola Pharmaceuticals

Media Contact:
Julie Normart
Pure Communications

Primary Logo

Portola Pharmaceuticals, Inc.